Mereo Biopharma Group Plc - ADR

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mereo BioPharma Group plc (NASDAQ: MREO) has announced topline efficacy and safety results from ASTRAEUS Phase 2 study of alvelestat (MPH-966) in severe alpha-1 antitrypsin deficiency-(AATD) associated emphysema. Emphysema is a lung disease caused by damage to the small air sacs in.

Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease

Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET

Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

MEREO BIOPHARMA (MREO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022, at 12:45pm Eastern Time.

Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

LONDON and REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results for the year ended December 31, 2021 and provided an update on recent corporate highlights.

Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights

LONDON and REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 8:00am Eastern Time.

Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference

The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO) announced topline data from a Phase 1b/2 trial of alvelestat in hospitalized COVID-19 Respiratory Disease patients. Consistent with the known safety profile of alvelestat, no safety signals were observed in lab safety monitoring, including none in liver, renal and vital sign parameters.

Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity

Alvelestat reported safe and well-tolerated in patients with COVID-19

UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease

Can-Fite BioPharma Ltd.

Digital Ally Inc

OPKO Health

Progenity

5 penny stocks to buy for under $5 right now. Are they worth the risk?

5 Penny Stocks To Buy For Under $5 This Week

LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced the presentation of data from the initial seven patients in an investigator-sponsored study of alvelestat in patients with BOS following hematopoietic stem cell transplantation (“HCT”). These data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, GA by Annie Im, MD, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA.

Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo's Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting

Mereo BioPharma Group plc (NASDAQ: MREO) reported interim data from ACTIVATE Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with Bristol Myers Squibb Co (NYSE: BMY) Opdivo (nivolumab) in select recurrent advanced/metastatic solid tumors. As of the cut-off date, one complete response in cervical cancer, one partial response in ovarian cancer, and four instances of stable disease in ovarian cancer, cervical cancer, and uveal melanoma were observed.

Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer

The stock price of Mereo BioPharma (NASDAQ: MREO) increased by over 1.5% pre-market today. This is why it happened.

Mereo BioPharma (MREO) Stock: Why The Price Increased Today

LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that data from an investigator-sponsored study of alvelestat in patients with Bronchiolitis Obliterans Syndrome (“BOS”) following hematopoietic stem cell transplantation (“HCT”) will be shared in a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, being held December 11-14, 2021 in Atlanta, Georgia and virtually.

Data from Investigator-sponsored Trial of Mereo BioPharma's alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

Senseonics Holdings

These two low-priced biotech stocks could produce life-changing returns for early shareholders.

2 Growth Stocks That Could Deliver 1,000% Returns

LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management.

Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

Mereo BioPharma Group plc (NASDAQ: MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with Bronchiolitis Obliterans Syndrome (BOS), following hematopoietic stem cell transplantation (HCT). The Phase 1b/2 study, being conducted under a Clinical Trial Agreement between Mereo and the National Cancer Institute, plans to recruit a total of 30 patients.

Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome

Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement. The partnership will support a Phase 1b/2 clinical study of etigilimab combined with an anti-PD-1 antibody in clear cell ovarian cancer to be conducted at MD Anderson.

Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab

LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 11:00am Eastern Time.

Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference

The shares of Mereo BioPharma Group plc (NASDAQ: MREO) have received a price target of $10 by Needham. These are the details.

Mereo BioPharma Stock Price: $10 Target By Needham

-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta ---- Further Strengthened Management Team ---- OncXerna Global Licensing Agreement for Navicixizumab ---- Strengthened Balance Sheet through Public and Private Financings and Business Development Transactions -- LONDON and REDWOOD CITY, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results and for the year ended December 31, 2020 and provided an update on recent corporate highlights.

Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights

Mereo BioPharma is a biopharma company focused on oncology and rare diseases, suiting a market cap of $388M USD at the time of this article. The company currently has great partnerships in place, which will increase the chances of success as well as my confidence as an investor.

Mereo BioPharma: An Overlooked Bio Company

LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00am Eastern Time.

Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously announced underwritten public offering of 39,675,000 American Depositary Shares (“ADSs”), at a public offering price of $2.90 per ADS, which includes 5,175,000 additional ADSs issued upon the exercise in full of the underwriters' option to purchase additional ADSs. Each ADS represents five ordinary shares of Mereo. The aggregate gross proceeds to Mereo from the offering, before deducting underwriting discounts and commissions and offering expenses were $115.1 million. All of the ADSs in the offering were sold by Mereo.

Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritten public offering of 34,500,000 American Depositary Shares (“ADSs”) at a public offering price of $2.90 per ADS. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $100.1 million. In addition, Mereo has granted the underwriters a 30-day option to purchase up to 5,175,000 additional ADSs at the public offering price, less underwriting discounts and commissions. Each ADS represents five ordinary shares of Mereo. All of the ADSs in the offering will be sold by Mereo. The offering is expected to close on or about February 12, 2021, subject to the satisfaction of customary closing conditions.

News for Mereo Biopharma Group Plc - ADR Stock (MREO)